摘要
目的:观察增强剂量CTOP方案治疗NHL(非霍奇金淋巴瘤)的疗效及不良反应,进而探讨提高THP(吡柔比星)在联合化疗方案中的剂量强度的安全性。方法:39例初治NHL随机分为两组分别接受常规剂量CTOP(THP40mg/m2)和增强剂量CTOP(THP60mg/m2)方案化疗至少2疗程,观察疗效及不良反应。结果:增强剂量CTOP与常规剂量CTOP方案相比完全缓解率有所提高(47.4%:21.1%),达到完全缓解的时间也缩短(P<0.01);而且提高THP剂量强度后并未增加心脏毒性、脱发及骨髓抑制等不良反应的发生,两组的不良反应发生率及严重程度相仿,无显著性差异。结论:增强剂量CTOP方案治疗NHL可提高疗效而不加重不良反应,增强剂量吡柔比星可安全使用。
Objective：To evaluate the response of escalated CTOP consisting of increased dose THP（60mg/m^2）in NHL and clarify how the side-effect oceur （especially for the occurrecce of cardiotoxicity）when the total dose of THP（pirarubicin）is increased.To study the safty of increasing the dose of THP.Methods：From August 2001 to May 2003,39 patients with chemonaive NHL（non Hodgkin＇s lymphoma）received either escalated CTOP（n=19） or conventional CTOP（n=20）.All these patients received 2 cycles chemotherapy at least.The response and side effect were observed after receiving chemotherapy.Results：Escalated CTOP achieved better complete remission rate thar conventional CTOP（47.4%vs21.1%）.Time to achieved complete remission was shortened,too（P〈0.01）.As to the side effect the escalated CTOP is similar to conventional CTOP.There was no significant difference between the two protocols.Conclusion：Incerment of the THP dose consisted in CTOP regimen can improve efficacy.On the other hand,chemotherpapy-induced toxicity was not significant intensified when dose of THP increased.The escalated THP can be used safely.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2005年第17期988-990,997,共4页
Chinese Journal of Clinical Oncology
